Oxnard firm helps area cities meet new climate rules
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Opinion: Witness to or maker of history
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
FTC settles lawsuit, paves way for Amgen’s $28B purchase of Horizon Therapeutics
The Federal Trade Commission entered into a consent agreement with Amgen and Horizon Therapeutics, clearing the way for Amgen’s $28 billion acquisition of Horizon to go through. Announced on Sept. 1, Amgen agreed to not use its drug list to inhibit competition for Tepezza and Krystezza, which are Horizon’s biggest two drugs and the only Read More →
Street smarts: Jordano shares 108-year-old history at Rotary Club meeting
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Mid-size companies expect growth despite economic hurdles
As part of a weekly partnership with KEYT, co-managing editor Jorge Mercado spoke with KEYT anchors Scott Hennessee and Beth Farnsworth to discuss this story. The link to the interview is here. Despite economic challenges and regulatory hurdles, Santa Barbara-based Aptitude Medical knows it’s on the cusp of hitting its potential, and it’s that knowledge Read More →
Portfolio watch
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
FTC pauses suit against Amgen on $28B acquisition
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
